Transforming growth factor-beta signaling and tumor angiogenesis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Transforming growth factor-beta (TGF-beta) family members are secreted multifunctional cytokines that play pivotal roles in development and disease. The prototypic member of this family, TGF-beta, plays a dual role in carcinogenesis, acting as a tumor suppressor in early stages and as tumor promoter in late stages of tumor progression. Numerous studies support the notion that pathological angiogenesis is one of the hallmarks of cancer. Tumor angiogenesis is regulated by a network of growth factors, including members of the TGF-beta family. TGF-beta acts in a context-dependent manner and can either stimulate or inhibit tumor angiogenesis. In this review, we discuss our current understanding on how TGF-beta family members affect endothelial and smooth muscle cell function and how perturbed TGF-beta signaling may contribute to tumor angiogenesis and tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Endothelial/Pericyte Interactions
Armulik, A., Abramsson, A., & Betsholtz, C. (2005) · Circulation Research · doi:10.1161/01.res.0000182903.16652.d7 · Cited by 2,048 · cited 1×
“Collectively, this suggests that pericytes and VSMCs may be potential therapeutic targets (55,56).”
BackgroundSPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS
Feng, X.-H., & Derynck, R. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.022404.142018 · Cited by 1,869
Soluble endoglin contributes to the pathogenesis of preeclampsia
Venkatesha, S., Toporsian, M., Lam, C., Hanai, J.-I., Mammoto, T., Kim, Y. M., Bdolah, Y., Lim, K.-H., Yuan, H.-T., Libermann, T. A., et al. (2006) · Nature Medicine · doi:10.1038/nm1429 · Cited by 1,855 · cited 1×
“Soluble Betaglycan and Endoglin have both been shown to interfere with the TGF-beta signaling pathway (24,25).”
BackgroundDefective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice
Dickson, M. C., Martin, J. S., Cousins, F. M., Kulkarni, A. B., Karlsson, S., & Akhurst, R. J. (1995) · Development · doi:10.1242/dev.121.6.1845 · Cited by 1,029
Pertovaara, L., Kaipainen, A., Mustonen, T., Orpana, A., Ferrara, N., Saksela, O., & Alitalo, K. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37365-9 · Cited by 694 · cited 1×
“In addition, TGF-beta can recruit inflammatory cells that produce angiogenic signals (113).”
BackgroundAbnormal angiogenesis but intact hematopoietic potential in TGF‐β type I receptor‐deficient mice
Larsson, J., Goumans, M., Sjöstrand, L. J., van Rooijen, M. A., Ward, D., Levéen, P., Xu, X., ten Dijke, P., Mummery, C. L., & Karlsson, S. (2001) · The EMBO Journal · doi:10.1093/emboj/20.7.1663 · Cited by 563 · cited 1×
“Mice deficient in TbRI expression die also at midgestation due to severe defects in vascular development of yolk sac and placenta (78).”
BackgroundYang, E. Y., & Moses, H. L. (1990) · The Journal of cell biology · doi:10.1083/jcb.111.2.731 · Cited by 464
Halder, S. K., Beauchamp, R. D., & Datta, P. K. (2005) · Neoplasia · doi:10.1593/neo.04640 · Cited by 288 · cited 1×
“SB-431542, a TbRI/ALK5 kinase inhibitor, was shown to inhibit the tumor-promoting effects of TGF-beta, including TGF-beta-induced EMT, cell motility, migration and invasion, and VEGF secretion in human cancer cell lines (108-110).”
Background
Cited by
Engineering biocompatible implant surfaces
Bauer, S., Schmuki, P., von der Mark, K., & Park, J. (2013) · Progress in Materials Science · doi:10.1016/j.pmatsci.2012.09.001 · Cited by 780
Transport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749
Signaling by members of the TGF-β family in vascular morphogenesis and disease
Pardali, E., Goumans, M.-J., & ten Dijke, P. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.06.006 · Cited by 401
Self-citationTransforming growth factor-β in myocardial disease
Frangogiannis, N. G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00646-w · Cited by 344
Transforming growth factor β as regulator of cancer stemness and metastasis
Bellomo, C., Caja, L., & Moustakas, A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.255 · Cited by 235
Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis
Cao, Y. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.002 · Cited by 190
The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance
Ahmed, S., Bradshaw, A.-D., Gera, S., Dewan, M., & Xu, R. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6010005 · Cited by 174
“A major factor for this vascularization is vascular endothelial growth factor (VEGF), which is induced by TGF-β.”
BackgroundBAMBI Elimination Enhances Alternative TGF-β Signaling and Glomerular Dysfunction in Diabetic Mice
Fan, Y., Li, X., Xiao, W., Fu, J., Harris, R. C., Lindenmeyer, M., Cohen, C. D., Guillot, N., Baron, M. H., Wang, N., et al. (2015) · Diabetes · doi:10.2337/db14-1397 · Cited by 57
Metadata
- Authors
- Pardali, E.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2009
- Volume
- 14
- Issue
- 1
- Pages
- 4848
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/3573
- OpenAlex
- W2076730388
- Cited by
- 117
- References
- 9
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.